A Phase II study of gemcitabine and docetaxel in patients with metastatic pancreatic carcinoma

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1002/cncr.10202PMID 11815964
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Phase II trial of gemcitabine (2,2′-difiuorodeoxycytidine) in patients with adenocarcinoma of the pancreas

  2004cited by this paper
• Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer.

  2001cited by this paper
• A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors

  2000cited by this paper
• Pancreatic cancer: State‐of‐the‐art care

  2000cited by this paper
• Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer.

  2000cited by this paper
• A phase II trial of biweekly high dose gemcitabine for patients with metastatic pancreatic adenocarcinoma

  2000cited by this paper
• A phase II study: docetaxel as first-line chemotherapy for advanced pancreatic adenocarcinoma.

  2000cited by this paper
• A Phase II Study of Gemcitabine and 5-Fluorouracil in Metastatic Pancreatic Cancer: An Eastern Cooperative Oncology Group Study (E3296)

  2000cited by this paper
• Cancer statistics, 2000

  2000cited by this paper
• A phase I-II study of gemcitabine and docetaxel in advanced pancreatic cancer: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

  1999cited by this paper
• Docetaxel and gemcitabine activity in NSCLC cell lines and in primary cultures from human lung cancer

  1999cited by this paper
• Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study.

  1999cited by this paper
• Chemotherapy for advanced pancreatic cancer: it may no longer be ignored.

  1999cited by this paper
• Phase II study of docetaxel in patients with metastatic pancreatic cancer: a Japanese cooperative study

  1999cited by this paper
• Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer.

  1999cited by this paper
• A combination of gemcitabine and 5-fluorouracil in advanced pancreatic cancer, a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD)

  1999cited by this paper
• Phase II trial of gemcitabine, epirubicin and granulocyte colony-stimulating factor in patients with advanced pancreatic adenocarcinoma

  1999cited by this paper
• Phase I study of docetaxel dose escalation in combination with fixed weekly gemcitabine in patients with advanced malignancies.

  1998cited by this paper
• Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study.

  1997cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Phase II study of gemcitabine in patients with advanced pancreatic cancer.

  1996cited by this paper
• Cancer statistics

  1989cited by this paper
• Optimal two-stage designs for phase II clinical trials.

  1989cited by this paper
• Nonparametric Estimation from Incomplete Observations

  1958cited by this paper

• SMPR: a structure-enhanced multimodal drug‒disease prediction model for drug repositioning and cold start

  2025cites this paper
• A sphingolipid-derived paclitaxel nanovesicle enhances efficacy of combination therapies in triple-negative breast cancer and pancreatic cancer

  2025cites this paper
• Nab-Paclitaxel in the Treatment of Gastrointestinal Cancers—Improvements in Clinical Efficacy and Safety

  2023cites this paper
• Docetaxel-loaded borage seed oil nanoemulsion with improved antitumor activity for solid tumor treatment: Formulation development, in vitro, in silico and in vivo evaluation

  2022cites this paper
• Targeting Casein Kinase 1 Delta Sensitizes Pancreatic and Bladder Cancer Cells to Gemcitabine Treatment by Upregulating Deoxycytidine Kinase

  2020cites this paper
• Galactosylated TPGS Micelles for Docetaxel Targeting to Hepatic Carcinoma: Development, Characterization, and Biodistribution Study

  2020cites this paper
• Evaluation of Phase II Trial Design in Advanced Pancreatic Cancer.

  2019cites this paper
• Phase I study of third-line palliative chemotherapy with low dose paclitaxel for pancreatic cancer.

  2018cites this paper
• Phase I study of weekly palliative chemotherapy with low-dose third-line paclitaxel for biliary tract cancer.

  2017cites this paper
• Mechanistic Study of Inhibitory Effects of Atorvastatin and Docetaxel in Combination on Prostate Cancer.

  2016cites this paper
• Targeting docetaxel-PLA nanoparticles simultaneously inhibit tumor growth and liver metastases of small cell lung cancer.

  2015cites this paper
• Preparation,-Characterization and Anti-Glioma Effects of Docetaxel-Incorporated Albumin-Lipid Nanoparticles.

  2015cites this paper
• Nanoparticle albumin-bound (nab)-paclitaxel for the treatment of pancreas ductal adenocarcinoma

  2015cites this paper
• 20-(s)-Ginsenoside Rg3 induces apoptotic cell death in human leukemic U937 and HL-60 cells through PI3K/Akt pathways

  2014cites this paper
• Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer

  2014cites this paper
• Emerging treatments for advanced pancreatic cancer: clinical potential of albumin-bound paclitaxel

  2014cites this paper
• THE EFFECTS OF METFORMIN ON PANCREATIC CANCER METABOLISM

  2014cites this paper
• Chemotherapy for advanced cancers.

  2014cites this paper
• Nab-paclitaxel: potential for the treatment of advanced pancreatic cancer

  2014cites this paper
• Taxanes: impact on pancreatic cancer

  2014cites this paper
• Study and evaluation of mechanisms of dual targeting drug delivery system with tumor microenvironment assays compared with normal assays.

  2014cites this paper
• Comparative benefits of nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.

  2013cites this paper
• Comparative benefits of Nab-paclitaxel over gemcitabine or polysorbate-based docetaxel in experimental pancreatic cancer.

  2013cites this paper
• The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer

  2013cites this paper
• Anti-glioma effect and safety of docetaxel-loaded nanoemulsion

  2012cites this paper
• nab-Paclitaxel potentiates gemcitabine activity by reducing cytidine deaminase levels in a mouse model of pancreatic cancer.

  2012cites this paper
• Significance of combination therapy of zoledronic acid and gemcitabine on pancreatic cancer

  2012cites this paper
• CYTOTOXITY EVALUATION OF DOCETAXEL NANOPARTICLES BY CULTURING HEPG2 CARCINOMA CELL LINES

  2012cites this paper
• Cytotoxic Chemotherapy for Pancreatic Cancer

  2012cites this paper
• Role of taxanes in pancreatic cancer.

  2012cites this paper
• Successful treatment of unresectable gallbladder cancer with low-dose paclitaxel as palliative chemotherapy after failure of gemcitabine and oral S-1: A case report.

  2012cites this paper
• Enhanced oral bioavailability and anti‐tumour effect of paclitaxel by 20(s)‐ginsenoside Rg3 in vivo

  2012cites this paper
• Docetaxel Obs Cancer BPL 01 2012

  2012cites this paper
• Medical treatment of pancreatic cancer: new hopes after 10 years of gemcitabine.

  2011cites this paper
• Pulmonary toxicity among cancer patients treated with a combination of docetaxel and gemcitabine: a meta-analysis of clinical trials

  2011cites this paper
• Combination of ginsenoside Rg3 with docetaxel enhances the susceptibility of prostate cancer cells via inhibition of NF-kappaB.

  2010cites this paper
• Recent developments in palliative chemotherapy for locally advanced and metastatic pancreas cancer.

  2010cites this paper
• Metastatic pancreatic cancer: is gemcitabine still the best standard treatment? (Review).

  2010cites this paper
• Metastatic Pancreatic Cancer: Systemic Therapy

  2010cites this paper
• The characteristics and performance of a multifunctional nanoassembly system for the co-delivery of docetaxel and iSur-pDNA in a mouse hepatocellular carcinoma model.

  2010cites this paper
• Interaction of the docetaxel with human serum albumin using optical spectroscopy methods

  2009cites this paper
• A Phase 2 Trial of Glufosfamide in Combination With Gemcitabine in Chemotherapy-Naive Pancreatic Adenocarcinoma

  2009cites this paper
• Anti-Cancer Effect of the Combination of Thiacremonone and Docetaxel by Inactivation of NF-κB in Human Cancer Cells

  2009cites this paper
• Inhibition of NF-κB by ginsenoside Rg3 enhances the susceptibility of colon cancer cells to docetaxel

  2009cites this paper
• Obovatol enhances docetaxel-induced prostate and colon cancer cell death through inactivation of nuclear transcription factor-kappaB.

  2009cites this paper
• Targeted therapies for pancreatic adenocarcinoma.

  2009cites this paper
• The performance of docetaxel-loaded solid lipid nanoparticles targeted to hepatocellular carcinoma.

  2009cites this paper
• Oncological Management of Pancreatic Cancer in Advanced Stages

  2008cites this paper
• Pancreatic cancer--is the wall crumbling?

  2008cites this paper
• Gemcitabine in the treatment of metastatic pancreatic cancer

  2008cites this paper
• Weekly Docetaxel as Salvage Therapy in Patients with Gemcitabine-Refractory Metastatic Pancreatic Cancer

  2008cites this paper
• Endoscopic electrolytic ablation : feasibility and safety in the treatment of pancreatic pathologies

  2007cites this paper
• Class III β‐tubulin, a marker of resistance to paclitaxel, is overexpressed in pancreatic ductal adenocarcinoma and intraepithelial neoplasia

  2007cites this paper
• Transarterielle Chemoperfusion mit Gemcitabine und Mitomycin C bei Pankreaskarzinom: Ergebnisse bei Rezidivtumoren und fortgeschrittenen Tumorstadien

  2007cites this paper
• Intra-arterial chemotherapy of advanced pancreatic cancer: a single center experience.

  2007cites this paper
• [Transarterial chemoperfusion with gemcitabine and mitomycin C in pancreatic carcinoma: results in locally recurrent tumors and advanced tumor stages].

  2007cites this paper
• Phase II Study of Cisplatin Combined with Weekly Gemcitabine in the Treatment of Patients with Metastatic Pancreatic Carcinoma

  2007cites this paper
• Docetaxel and gemcitabine combination therapy in advanced transitional cell carcinoma of the urothelium: results of a phase II and pharmacologic study

  2007cites this paper
• Chemotherapy for Pancreatic Cancer: From Metastatic Disease to Adjuvant Therapy

  2007cites this paper
• Gemcitabine combined with 5-fluorouracil for the treatment of advanced carcinoma of the pancreas.

  2006cites this paper
• Clinical Activity of Gemcitabine as a Single Agent and in Combination

  2006cites this paper
• Peritumoral injection of adenovirus vector expressing NK4 combined with gemcitabine treatment suppresses growth and metastasis of human pancreatic cancer cells implanted orthotopically in nude mice and prolongs survival

  2006cites this paper
• Chemotherapy for advanced pancreatic cancer.

  2006cites this paper
• Cytotoxic chemotherapy for pancreatic cancer: Advances to date and future directions.

  2006cites this paper
• Clinical experiences with G17DT in gastrointestinal malignancies

  2006cites this paper
• An Evidence-Based Approach to the Management of Pancreatic Cancer

  2006cites this paper
• Oxaliplatin combined with 5-FU in second line treatment of advanced pancreatic adenocarcinoma. Results of a phase II trial.

  2006cites this paper
• Multicenter phase-I/II study using a combination of gemcitabine and docetaxel in metastasized and unresectable, locally advanced pancreatic carcinoma.

  2006cites this paper
• Docetaxel plus gemcitabine or docetaxel plus cisplatin in advanced pancreatic carcinoma: randomized phase II study 40984 of the European Organisation for Research and Treatment of Cancer Gastrointestinal Group.

  2005cites this paper
• Combination chemotherapy with gemcitabine and biotherapy with opioid growth factor (OGF) enhances the growth inhibition of pancreatic adenocarcinoma

  2005cites this paper
• Pharmacokinetics of the Antineoplastic Drug Mitomycin C in Regional Chemotherapy Using the Aortic Stop Flow Technique in Advanced Pancreatic Carcinoma

  2005cites this paper
• RNA interference targeting aurora kinase a suppresses tumor growth and enhances the taxane chemosensitivity in human pancreatic cancer cells.

  2005cites this paper
• Docetaxel/Gemcitabine Followed by Gemcitabine and External Beam Radiotherapy in Patients With Pancreatic Adenocarcinoma

  2005cites this paper
• Treatment for pancreatic cancer: current therapy and continued progress.

  2005cites this paper
• Noninvasive assessment of tumor vascularity by contrast‐enhanced ultrasonography and the prognosis of patients with nonresectable pancreatic carcinoma

  2005cites this paper
• Docetaxel in the management of advanced pancreatic cancer.

  2005cites this paper
• Gemcitabine: A Review of its Use in the Management of Pancreatic Cancer

  2005cites this paper
• Evolution de la prise en charge palliative du cancer du pancréas avancé en relation avec l'arrivée de nouveaux médicaments : implications sur la survie et considérations médico-économiques

  2005cites this paper
• Phase I Trial Using Weekly Administration of Gemcitabine and Docetaxel in Patients with Advanced Pancreatic Carcinoma

  2004cites this paper
• Pancreatic cancer: future outlook, promising trials, newer systemic agents, and strategies from the Gastrointestinal Intergroup Pancreatic Cancer Task Force.

  2004cites this paper
• Pancreatic cancer

  2004cites this paper
• Phase II study of cisplatin, gemcitabine and 5-fluorouracil in advanced pancreatic cancer.

  2004cites this paper
• Apoptosis-Inducing Effect of Chemotherapeutic Agents Is Potentiated by Soy Isoflavone Genistein, a Natural Inhibitor of NF-κB in BxPC-3 Pancreatic Cancer Cell Line

  2004cites this paper
• Phase II Study of Gemcitabine in Combination with Docetaxel in Patients with Advanced Pancreatic Carcinoma (E1298)

  2004cites this paper
• Transarterielle Chemoperfusion des inoperablen Pankreaskarzinoms und Lokalrezidivs

  2003cites this paper
• Weekly gemcitabine and cisplatin chemotherapy: a well-tolerated but ineffective chemotherapeutic regimen in advanced pancreatic cancer patients. A report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD).

  2003cites this paper
• RETRACTED: Biotherapeutic approaches to pancreatic cancer

  2003cites this paper
• Phase II Study of Gemcitabine plus Docetaxel in Advanced Pancreatic Cancer: A Hoosier Oncology Group Study

  2003cites this paper
• A phase II study of mitomycin C, cisplatin and protracted infusional 5-fluorouracil in advanced pancreatic carcinoma: efficacy and low toxicity.

  2003cites this paper
• Chemotherapeutic advances in pancreatic cancer

  2003cites this paper
• The DNA methylation inhibitor 5-azacytidine modulates 6-thioguanine toxicity in mammalian cells.

  2003cites this paper
• Advanced pancreatic cancer: is there a role for combination therapy?

  2003cites this paper
• Docetaxel inhibits SMMC-7721 human hepatocellular carcinoma cells growth and induces apoptosis.

  2003cites this paper
• Intra-Arterial Infusion Chemotherapy With Angiotensin-II for Locally Advanced and Nonresectable Pancreatic Adenocarcinoma: Further Evaluation and Prognostic Implications

  2003cites this paper
• Management of pancreatic cancer

  2003cites this paper
• [Transarterial chemoperfusion of inoperable pancreas carcinoma and local recurrence].

  2003cites this paper
• Recent developments in the pharmacological treatment of advanced pancreatic cancer

  2003cites this paper
• The medical management of pancreatic cancer: a review.

  2003influential citation
• Modulating cell cycle: current applications and prospects for future drug development.

  2002cites this paper
• Metastatic pancreatic cancer

  2002influential citation